NEW YORK, March 15 – Arena Pharmaceuticals has enlisted the help of Celera’s databases and bioinformatics tools to identify G protein-coupled receptors (GPCRs), the companies said Thursday. 

Financial terms of Arena's multi-year subscription to the Celera Discovery System were not disclosed, but Celera has previously said that non-academic subcribers pay $5 million to $15 million a year. After signing Arena, Celera now has eight known commercial subscribers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.